- MedImmune - Wikipedia
MedImmune conducted successful clinical trials for a new generation of FluMist needle-free vaccine, called CAIV-T, which was approved by the U S Food and Drug Administration (FDA) in 2007, and is now the form offered on the market
- MedImmune - LinkedIn
MedImmune is pioneering innovative research and exploring novel pathways across Oncology, Respiratory, Cardiovascular, Renal and Metabolic Diseases, and Infection and Vaccines
- MedImmune - AstraZeneca
MedImmune is progressing a next generation, extended half-life mAb for RSV Target • Novel, neutralizing epitope on the RSV F protein, located on the surface of the virion
- AstraZeneca retires Medimmune name amid sales turnaround
After 30 years of drug development, MedImmune will cease to exist as an industry name now that owner AstraZeneca has decided to retire the brand as part of ongoing restructuring efforts
- MedImmune, LLC | (301) 398-0000 | Gaithersburg, Maryland - AllBiz
MedImmune, LLC is a fully integrated biopharmaceutical company that focuses on developing and marketing products addressing medical needs in infectious disease, immune regulation, and cancer
- MedImmune, Inc. -- Company History
MedImmune is a fully integrated biopharmaceutical company focused on developing and marketing products that address medical needs in areas such as infectious disease, immune regulation and cancer
- MedImmune - 2025 Company Profile Team - Tracxn
MedImmune is an acquired company based in Gaithersburg (United States), founded in 1987 It operates as a Biologic R D for oncology; respiratory, inflammation and autoimmune; and cardiovascular and metabolic diseases
- MedImmune (biologics division of AstraZeneca) - [LSUS] Life-Sciences . . .
MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines
|